Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

2 years ago

Four poster presentations provided detailed and new data on the achievement of primary and secondary endpoints, improvements in investigator-rated outcomes,…

MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer

2 years ago

CARMEL, Ind., July 10, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™…

Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax

2 years ago

-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement…

iCAD Offers ROI Analysis Based on Real-World Results from its ProFound Breast AI Suite at AHRA Annual Meeting

2 years ago

Company’s ROI Tool offers preview of business value the ProFound Breast AI Suite offers to clinicians and imaging facilitiesNASHUA, N.H.,…

Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)

2 years ago

10 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Completion of Enrolment and Treatment in the Phase 1 Study of MTX110…

Konica Minolta Announces Significant Expansion of Dynamic Digital Radiography Across Multiple Facility Types and Clinical Care Areas

2 years ago

Dynamic Digital Radiography - Neck motion Dynamic Digital Radiography (DDR) is the next evolution in X-ray, enabling clinicians to view…

Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors

2 years ago

MIAMI, July 10, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing…

LifeArc and DEBRA Austria launch £2.5 million funding call for repurposing therapies for epidermolysis bullosa

2 years ago

LifeArc and DEBRA Austria launch £2.5 million funding callfor repurposing therapies for epidermolysis bullosa New call for projects for treatments…

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

2 years ago

Company to voluntarily delist from the Toronto Stock Exchange (TSX)Last trading day on TSX will be July 21, 2023 TORONTO, Ontario…